Abstract
Human liver and kidney organ slices were used to investigate the biotransformation competence of the slices in combination with several markers of cell viability and function. The immunosuppressant cyclosporin A (CSA) is extensively metabolized in liver slices to the three known primary metabolites and many secondary metabolites. In kidney cortex slices the biotransformation of CSA is far more pronounced in humans than in rats. In human liver slices, levels of CYP3A, the proteins metabolizing CSA, are depressed about 25% by 1 and 10 μmol/L CSA within 24 h, indicating that high blood or tissue concentrations will inhibit CSA clearance.
A clinical marker for liver damage is the release of cellular α-glutathione-S-transferases (αGST). In this study the αGST levels were used to assess donor organ quality, organ slice incubation conditions, and compound exposure. A marker for cell death in human cells is the solubilization and release of nuclear matrix proteins (Numa). Increases were apparent only after 48 h of culture.
A side-effect of CSA is that it induces hypertension and perturbs the lipid profile of transplant recipients. A potential marker for lipid disturbances is levels of serum lipoprotein (a) (Lp(a)), which is synthesized in the liver and found only in humans, apes, and nonhuman primates. CSA increases Lp(a) levels in the human liver slice cultures about 2-fold.
This study has demonstrated that the biotransformation capability of the organ slices contributes to the optimization of thein vitro system and to the evaluation of markers for drug induced side-effects or toxicity. Assays were identified that could be used clinically to monitor CSA-induced organ damage or rejection (αGST), hypertension (Lp(a)), and toxicity (Numa).
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Abbreviations
- αGST:
-
α-glutathione-S-transferases
- CSA:
-
cyclosporin A
- CYP3A:
-
cytochrome P4503A
- CSX:
-
undefined cyclosporin
- Lp(a):
-
lipoprotein (a)
- IMM:
-
SDZ IMM 125
- Numa:
-
nuclear matrix proteins
References
Beckett GJ, Hayes JD. GlutathioneS-transferases: biomedical applications. Adv Clin Chem 1993;30:281–380.
Berridge M, Tan A. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): Subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch Biochem Biophys. 1993;303:474–82.
Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.
Brown J, Anwar N, Short C et al. Serum lipoprotein (a) in renal transplant recipients receiving cyclosporin monotherapy. Nephrol Dial Transplant. 1993;8:863–7.
Copeland KR, Thliveris, JA, Yatscoff RW. Toxicity of cyclosporine metabolites. Therapeutic Drug Monitoring. 1990;12:525–32.
Khan D, Cervio G, Mazzagerro Z et al. Relationship between the dose and whole blood level of cyclosporine after liver and kidney transplantation. J Clin Lab Immunol 1992;37:163–71.
Kostner G. Interaction of Lp(a) and of Apo(a) with liver cells. Arteriosclerosis and Thrombosis. 1993;13:1101–9.
Kronbach T, Flischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450 gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther. 1988;43:630–5.
Lemoine A, Azoulay D, Gries JM et al. Relationship between graft cytochrome P-450 3A content and early morbidity after liver transplantation. Transplantation. 1993;55:1410–4.
Lucey MR, Kolare JC, Merion RM, Campbell DA, Aldrich M, Watkins PB. Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450IIIA. Lancet. 1990;335:11–5.
Malmendier C, Lontie J, Mathe D, Adam R, Bismuth H. Lipid and apolipoprotein changes after orthotopic liver transplantation for end-stage liver diseases. Clin Chim Acta. 1992;209:169–77.
Mason J. Pharmacology of cyclosporine (Sandimmune). Pathophysiology and toxicology of cyclosporine in humans and animals. Pharmacol Rev. 1990;42:423–34.
Maurer G, Loosli HR, Schreier E, Keller B. Disposition of cyclosporine in several animal species and man. I. Structural clucidation of its metabolites. Drug Metab Dispos. 1984;12:120–6.
Miller T, Beausang LA, Meneghini M, Lidgard L. Death-induced changes to the nuclear matrix: the use of anti-nuclear matrix antibodies to study agents of apotosis. Biotechniques. 1993;15:1042–7.
Rettig R, Schmitt B, Pelzl B, Speck T. The kidney and primary hypertension: contributions from renal transplantation studies in animals and humans. J Hypertension. 1993;11:883–91.
Scanu A. Structural basis for the presumptive atherothrombogenic action of lipoprotein (a). Biochem Pharmacol. 1993;46: 1675–80.
Sturrock N, Lang CC, Struthers A. Cyclosporin-induced hypertension precedes renal dysfunction and sodium retention in man. J Hypertension. 1993;11:1209–16.
Vickers AEM, Fischer V, Connors S et al., Cyclosporin A metabolism in human liver, kidney, and intestine slices. Comparison to rat and dog slices and human cell lines. Drug Metab Dispos. 1992;20:802–9.
Webb W, Reaveley D, O'Donnell M, O'Connor B, Seed M, Brown E. Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients? Lancet. 1993;341:268–70.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vickers, A.E.M. Use of human organ slices to evaluate the biotransformation and drug-induced side-effects of pharmaceuticals. Cell Biol Toxicol 10, 407–414 (1994). https://doi.org/10.1007/BF00755790
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00755790